Blocking the binding of TGF‐β1 to Ex‐TβRII, by means of administration of soluble TGF‐β type II receptor (sTβR)12 or the anti‐TGF‐β1 antibody,13 has become an option for ameliorating PF. The gene discussed is TGFB1; the disease is pemphigus foliaceus.